journal article·2020-11Open access

Mucin‐Inspired, High Molecular Weight Virus Binding Inhibitors Show Biphasic Binding Behavior to Influenza A Viruses

Matthias Wallert, Chuanxiong Nie, Parambath Anilkumar, Srinivas Abbina, Sumati Bhatia, Kai Ludwig, Jayachandran N. Kizhakkedathu, Rainer Haag, Stephan Block

Small· Volume 16· Issue 47

Abstract

Abstract Multivalent binding inhibitors are a promising new class of antivirals that prevent virus infections by inhibiting virus binding to cell membranes. The design of these inhibitors is challenging as many properties, for example, inhibitor size and functionalization with virus attachment factors, strongly influence the inhibition efficiency. Here, virus binding inhibitors are synthesized, the size and functionalization of which are inspired by mucins, which are naturally occurring glycosylated proteins with high molecular weight (MDa range) and interact efficiently with various viruses. Hyperbranched polyglycerols (hPGs) with molecular weights ranging between 10 and 2600 kDa are synthesized, thereby hitting the size of mucins and allowing for determining the impact of inhibitor size on the inhibition efficiency. The hPGs are functionalized with sialic acids and sulfates, as suggested from the structure of mucins, and their inhibition efficiency is determined by probing the inhibition of influenza A virus (IAV) binding to membranes using various methods. The largest, mucin‐sized inhibitor shows potent inhibition at pm concentrations, while the inhibition efficiency decreases with decreasing the molecular weight. Interestingly, the concentration‐dependent IAV inhibition shows a biphasic behavior, which is attributed to differences in the binding affinity of the inhibitors to the two IAV envelope proteins, neuraminidase, and hemagglutinin.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Influenza Virus Research Studies · Monoclonal and Polyclonal Antibodies Research · Virus-based gene therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Chemistry and Biochemistry Emmy‐Noether Group “Bionanointerfaces” Freie Universität Berlin Takustr. 3 Berlin 14195 Germany

Institute of Chemistry and Biochemistry Macromolecular Chemistry Freie Universität Berlin Takustr. 3 Berlin 14195 Germany

Centre for Blood Research Life Sciences Institute Department of Pathology and Laboratory Medicine University of British Columbia 2350 Health Sciences Mall Vancouver British Columbia V6T 1Z3 Canada

Research Center for Electron Microscopy and Core Facility BioSupraMol Institute of Chemistry and Biochemistry Freie Universität Berlin Fabeckstr. 36a Berlin 14195 Germany

Department of Chemistry University of British Columbia Vancouver British Columbia V6T 1Z3 Canada

School of Biomedical Engineering University of British Columbia Vancouver British Columbia V6T 1Z3 Canada

Funding

Deutsche Forschungsgemeinschaft · Freie Universität Berlin · Canadian Institutes of Health Research · Canada Foundation for Innovation · Michael Smith Foundation for Health Research

References (51)

Show source-provided references
1. 10.1016/j.cell.2020.02.05210.1016/j.cell.2020.02.052 ↗
2. 10.1016/S0140-6736(16)00006-410.1016/S0140-6736(16)00006-4 ↗
3. 10.1038/nature0815710.1038/nature08157 ↗
4. 10.1128/CMR.00102-1510.1128/CMR.00102-15 ↗
5. 10.1002/anie.20120111410.1002/anie.201201114 ↗
6. 10.1016/S1367-5931(00)00153-810.1016/S1367-5931(00)00153-8 ↗
7. 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-310.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3 ↗
8. 10.1039/b413971b10.1039/b413971b ↗
9. 10.1016/j.cell.2006.02.00710.1016/j.cell.2006.02.007 ↗
10. 10.1021/ja511408410.1021/ja5114084 ↗
11. 10.1016/j.copbio.2018.03.01010.1016/j.copbio.2018.03.010 ↗
12. 10.1056/NEJMra091006110.1056/NEJMra0910061 ↗
13. 10.1016/j.cocis.2005.11.00110.1016/j.cocis.2005.11.001 ↗
14. 10.1021/bc980099n10.1021/bc980099n ↗
15. 10.1002/adma.20090214410.1002/adma.200902144 ↗
16. Anilkumar P. · Nat. Commun. · 2020 · 11 · 213910.1038/s41467-020-15975-6 ↗
17. ul‐Hag M. I. · J. Polym. Sci., Part A: Polym. Chem. · 2013 · 51 · 261410.1002/pola.26649 ↗
18. 10.1016/j.addr.2008.09.00810.1016/j.addr.2008.09.008 ↗
19. 10.1021/bi00155a01310.1021/bi00155a013 ↗
20. 10.1038/s41594-019-0233-y10.1038/s41594-019-0233-y ↗
21. 10.1006/mthe.2002.057810.1006/mthe.2002.0578 ↗
22. 10.1021/acsinfecdis.7b0027010.1021/acsinfecdis.7b00270 ↗
23. 10.1016/0003-9861(87)90366-310.1016/0003-9861(87)90366-3 ↗
24. 10.1042/bj309080110.1042/bj3090801 ↗
25. 10.1002/anie.20200614510.1002/anie.202006145 ↗
26. 10.1016/j.biomaterials.2017.05.02810.1016/j.biomaterials.2017.05.028 ↗
27. 10.1038/s41565-020-0660-210.1038/s41565-020-0660-2 ↗
28. 10.1016/j.tim.2019.08.01010.1016/j.tim.2019.08.010 ↗
29. Hamming P. E. · Chem. Sci. · 2019 · 11 · 2710.1039/C9SC05149J ↗
30. 10.1002/rmv.35210.1002/rmv.352 ↗
31. 10.1371/journal.ppat.100723310.1371/journal.ppat.1007233 ↗
32. 10.1073/pnas.060761410310.1073/pnas.0607614103 ↗
33. 10.3389/fmicb.2019.0003910.3389/fmicb.2019.00039 ↗
34. Pedersen J. C. · 2008 · 5310.1007/978-1-59745-279-3_8 ↗
35. 10.1021/acs.nanolett.8b0496910.1021/acs.nanolett.8b04969 ↗
36. 10.1016/S0091-679X(08)60982-610.1016/S0091-679X(08)60982-6 ↗
37. 10.1016/S0378-1135(00)00167-X10.1016/S0378-1135(00)00167-X ↗
38. 10.1021/bi00447a01810.1021/bi00447a018 ↗
39. 10.1021/jm00021a00710.1021/jm00021a007 ↗
40. 10.1006/viro.1997.895810.1006/viro.1997.8958 ↗
41. 10.1371/journal.pone.016343710.1371/journal.pone.0163437 ↗
42. 10.1103/PhysRevLett.107.18810310.1103/PhysRevLett.107.188103 ↗
43. 10.1016/S0006-3495(86)83700-610.1016/S0006-3495(86)83700-6 ↗
44. 10.1128/JVI.01426-1210.1128/JVI.01426-12 ↗
45. 10.1021/acscentsci.8b0066610.1021/acscentsci.8b00666 ↗
46. 10.1002/rmv.187910.1002/rmv.1879 ↗
47. 10.3390/biom802003010.3390/biom8020030 ↗
48. 10.1128/JCM.43.8.4139-4146.200510.1128/JCM.43.8.4139-4146.2005 ↗
49. 10.1002/anie.20200483210.1002/anie.202004832 ↗
50. 10.1021/ma061348310.1021/ma0613483 ↗
51. 10.1021/ma802701g10.1021/ma802701g ↗